0001127602-15-028804.txt : 20151007 0001127602-15-028804.hdr.sgml : 20151007 20151007173114 ACCESSION NUMBER: 0001127602-15-028804 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151005 FILED AS OF DATE: 20151007 DATE AS OF CHANGE: 20151007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981007018 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LANDINE MICHAEL J CENTRAL INDEX KEY: 0001235600 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 151149685 MAIL ADDRESS: STREET 1: 88 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 021394136 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2015-10-05 0001520262 Alkermes plc. ALKS 0001235600 LANDINE MICHAEL J 852 WINTER ST. WALTHAM MA 02451 1 SVP, Corp Dev., Alkermes, Inc. Ordinary Shares 2015-10-05 4 A 0 5000 0 A 143680 D Ordinary Shares 2015-10-05 4 F 0 2356 59.77 D 141324 D Performance Restricted Stock Units 2015-10-05 4 A 0 5000 0 A Ordinary Shares 5000 5000 D Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc. Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil). /s/ Jennifer Baptiste, attorney-in-fact for Michael J. Landine 2015-10-07